Details of Disease

General Information of Disease (ID: DISZ2BNG)

• Disease Name: Polycystic ovarian syndrome
• Synonyms: hyperandrogenemia; PCO1; PCOS1; polycystic ovary syndrome 1; Stein-Leventhal synd.; Stein-Leventhal syndrome; PCOS; polycystic ovarian disease; polycystic ovaries; multicystic ovaries; polycystic ovary; polycystic ovary syndrome
• Disease Class: 5A80: Ovarian dysfunction
• Definition: A disorder that manifests as multiple cysts on the ovaries. It results in hormonal imbalances and leads to irregular and abnormal menstrual periods, excess growth of hair, acne eruptions and obesity.
• Disease Hierarchy:
  DISRGY2N: Endocrine disease
  DIS6SVEE: Syndromic disease
  DISYKSRF: Genetic disease
  DISZ2BNG: Polycystic ovarian syndrome
• ICD Code:
  ICD-11: ICD-11: 5A80.1
  ICD-10: ICD-10: E28.2
• Disease Identifiers:
  MONDO ID: MONDO_0008487
  MESH ID: D011085
  UMLS CUI: C0032460
  OMIM ID: 184700
  MedGen ID: 10836
  HPO ID: HP:0000147
  Orphanet ID: 3185
  SNOMED CT ID: 237055002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Histrelin	DM3D4FE	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
EX-404	DMDE9BX	Phase 2/3	NA	[2]
Thymoquinone	DMVDTR2	Phase 2/3	Small molecular drug	[3]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 158 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ACVR2B	TTLFRKS	Limited	Biomarker	[4]
ADRA1A	TTNGILX	Limited	Biomarker	[5]
ADRA1B	TTBRKXS	Limited	Biomarker	[5]
ADRA1D	TT34BHT	Limited	Biomarker	[5]
ENPP1	TTZTIWS	Limited	Biomarker	[6]
ERBB4	TTWALCO	Limited	Genetic Variation	[7]
HMGA2	TTSTVM0	Limited	Altered Expression	[8]
ITK	TT3C80U	Limited	Biomarker	[9]
LIPE	TTLUQ8E	Limited	Altered Expression	[10]
NGFR	TTEDJN4	Limited	Biomarker	[5]
AKT2	TTH24WI	moderate	Biomarker	[11]
CAV1	TTXUBN2	moderate	Altered Expression	[12]
CYP51A1	TT67TDP	moderate	Altered Expression	[13]
ERBB3	TTSINU2	moderate	Genetic Variation	[7]
FOS	TTOM5AU	moderate	Genetic Variation	[14]
GCK	TTDLNGZ	moderate	Biomarker	[15]
HSD17B1	TTIWB6L	moderate	Biomarker	[16]
KISS1R	TT3KBZY	moderate	Altered Expression	[17]
LCT	TTA0OSE	moderate	Biomarker	[18]
MC3R	TTNI91K	moderate	Genetic Variation	[19]
PLIN1	TTIV27N	moderate	Genetic Variation	[20]
ROR1	TTDEJAU	moderate	Altered Expression	[21]
SETD2	TTPC3H4	moderate	Altered Expression	[22]
SMAD6	TTON5JB	moderate	Altered Expression	[23]
STS	TTHM0R1	moderate	Altered Expression	[24]
TACR3	TTBPGLU	moderate	Altered Expression	[25]
TNFSF12	TTBTDM1	moderate	Biomarker	[26]
ACVR1	TTJNBQA	Strong	Genetic Variation	[27]
ACVR2A	TTX2DRI	Strong	Altered Expression	[28]
ADRB2	TTG8ZWP	Strong	Genetic Variation	[29]
ADRB3	TTMXGCW	Strong	Biomarker	[30]
AKR1B1	TTFBNVI	Strong	Biomarker	[31]
APLN	TT87D3J	Strong	Biomarker	[32]
APOA1	TT5S8DR	Strong	Genetic Variation	[33]
APOB	TTN1IE2	Strong	Biomarker	[34]
AQP7	TTNGCRK	Strong	Altered Expression	[35]
AQP9	TTQEI32	Strong	Altered Expression	[36]
ATF4	TTQCKWT	Strong	Altered Expression	[37]
AZGP1	TTUPYLV	Strong	Altered Expression	[38]
BAX	TTQ57WJ	Strong	Biomarker	[39]
BCL11A	TTR61MW	Strong	Biomarker	[40]
BCL2	TTFOUV4	Strong	Altered Expression	[41]
BLK	TTNDSC3	Strong	Genetic Variation	[42]
BMPR2	TTGKF90	Strong	Biomarker	[43]
CASP7	TTM7Y45	Strong	Altered Expression	[44]
CCNB1	TT9P6OW	Strong	Biomarker	[40]
CCNE2	TTLDRGX	Strong	Biomarker	[40]
CD36	TTPJMCU	Strong	Altered Expression	[45]
CDK2	TT7HF4W	Strong	Genetic Variation	[46]
CGA	TTFC29G	Strong	Altered Expression	[47]
CGB3	TTUH273	Strong	Altered Expression	[47]
CLDN4	TTMTS9H	Strong	Biomarker	[40]
CNP	TT71P0H	Strong	Biomarker	[48]
CPA1	TT3LJ6G	Strong	Biomarker	[49]
CPB2	TTP18AY	Strong	Altered Expression	[50]
CTF1	TTXGTZU	Strong	Biomarker	[51]
CYP11A1	TTSYVO6	Strong	Biomarker	[52]
CYP11B1	TTIQUX7	Strong	Biomarker	[53]
DCN	TTB3XAN	Strong	Biomarker	[21]
DLG4	TT9PB26	Strong	Biomarker	[40]
DMD	TTWLFXU	Strong	Biomarker	[54]
DNAJB1	TTPXAWS	Strong	Genetic Variation	[55]
DPP4	TTDIGC1	Strong	Altered Expression	[56]
EDN2	TTMR0OP	Strong	Altered Expression	[57]
EHMT1	TTOFXD7	Strong	Biomarker	[58]
EPHA7	TTAHTVG	Strong	Biomarker	[59]
EREG	TTYSB89	Strong	Biomarker	[60]
F13A1	TTXI2RA	Strong	Biomarker	[61]
FABP1	TTIV96N	Strong	Genetic Variation	[62]
FABP4	TTHWMFZ	Strong	Genetic Variation	[63]
FCGR1A	TTZK4I3	Strong	Altered Expression	[64]
FGF18	TT6ICRA	Strong	Biomarker	[40]
FGF19	TTGCH11	Strong	Altered Expression	[65]
FGG	TTR31L7	Strong	Biomarker	[66]
FKBP4	TTHY0FT	Strong	Altered Expression	[67]
FLT4	TTDCBX5	Strong	Biomarker	[40]
FOXO1	TTLRVIA	Strong	Altered Expression	[68]
FOXP3	TT1X3QF	Strong	Biomarker	[40]
FSHB	TT13GFV	Strong	Genetic Variation	[42]
G6PC	TTBQMJ8	Strong	Biomarker	[69]
GHRL	TT1OCL0	Strong	Genetic Variation	[70]
GIP	TT40HS5	Strong	Biomarker	[71]
GLIPR1	TTEQF1O	Strong	Genetic Variation	[42]
GNAQ	TTL1SRG	Strong	Genetic Variation	[72]
GPR3	TTHZVSK	Strong	Genetic Variation	[73]
HMGB2	TTA78JQ	Strong	Biomarker	[74]
HSD17B13	TTDJYZR	Strong	Altered Expression	[75]
HSD17B2	TT0PT1R	Strong	Biomarker	[76]
HSD17B4	TTL1WGS	Strong	Biomarker	[74]
HTR2C	TTWJBZ5	Strong	Biomarker	[77]
IDE	TT2EDHU	Strong	Genetic Variation	[78]
IGFBP1	TTCJTWF	Strong	Altered Expression	[79]
IGFBP6	TTLAYV8	Strong	Altered Expression	[80]
IKZF3	TTCZVFZ	Strong	Genetic Variation	[81]
INHBA	TTVB30D	Strong	Biomarker	[82]
KITLG	TTDJ51N	Strong	Biomarker	[83]
KLK3	TTS78AZ	Strong	Biomarker	[84]
LALBA	TTBRLU3	Strong	Biomarker	[85]
LEPR	TT0HD6V	Strong	Genetic Variation	[86]
LIF	TTGZ5WN	Strong	Altered Expression	[87]
LIFR	TTID542	Strong	Biomarker	[40]
LTK	TT1JZG6	Strong	Biomarker	[40]
LYN	TT1RWNJ	Strong	Biomarker	[88]
MAP3K4	TT1RSX7	Strong	Biomarker	[89]
MC4R	TTD0CIQ	Strong	Genetic Variation	[90]
MCM7	TT1RM3F	Strong	Altered Expression	[91]
MELTF	TT8OBT3	Strong	Biomarker	[92]
MMP2	TTLM12X	Strong	Altered Expression	[93]
MSTN	TTM8I2X	Strong	Altered Expression	[94]
MTNR1A	TT0WAIE	Strong	Genetic Variation	[95]
MUSK	TT6SA0X	Strong	Genetic Variation	[96]
NCOA4	TT8OY02	Strong	Biomarker	[97]
NPPC	TTRK0B9	Strong	Altered Expression	[48]
NPR2	TTNB7IF	Strong	Altered Expression	[48]
NRG1	TTEH395	Strong	Biomarker	[40]
PBK	TTMY6BZ	Strong	Biomarker	[40]
PCSK1	TTED9LZ	Strong	Biomarker	[6]
PDE3B	TTN34SQ	Strong	Biomarker	[40]
PDE8A	TTIS4OW	Strong	Biomarker	[98]
PDPK1	TTYMGWX	Strong	Altered Expression	[99]
PLA2G7	TTDNFMT	Strong	Genetic Variation	[33]
PMEL	TT8MK59	Strong	Genetic Variation	[46]
PPARGC1B	TTKSQ3W	Strong	Genetic Variation	[100]
PPP5C	TTTW7FJ	Strong	Altered Expression	[101]
PPT1	TTSQC14	Strong	Altered Expression	[101]
PRDX4	TTPBL9I	Strong	Altered Expression	[102]
PRKAR2B	TTW4Y2M	Strong	Biomarker	[103]
PRLR	TTBPXMA	Strong	Altered Expression	[104]
PTAFR	TTQL5VC	Strong	Biomarker	[40]
PTGDR	TTNVEIR	Strong	Biomarker	[105]
PTGER3	TTPNGDE	Strong	Biomarker	[40]
PTH	TT6F7GZ	Strong	Biomarker	[106]
RNF6	TT4S09X	Strong	Biomarker	[83]
RRM2	TT1S4LJ	Strong	Biomarker	[40]
RUNX3	TTKCVO7	Strong	Biomarker	[40]
S100A6	TT716MY	Strong	Altered Expression	[107]
SCT	TTOBVIN	Strong	Biomarker	[40]
SFRP4	TTX8I1Y	Strong	Altered Expression	[108]
SLC18A2	TTNZRI3	Strong	Genetic Variation	[109]
SLC37A4	TT1KPBZ	Strong	Genetic Variation	[110]
SLC47A1	TTMHCGA	Strong	Genetic Variation	[111]
SLC47A2	TT7HXSL	Strong	Genetic Variation	[111]
SOX5	TTXHSZK	Strong	Genetic Variation	[112]
SRD5A1	TTTU72V	Strong	Genetic Variation	[113]
SRD5A2	TTT02K8	Strong	Genetic Variation	[114]
SREBF2	TTRQ4AP	Strong	Genetic Variation	[115]
STAR	TTEI40H	Strong	Biomarker	[82]
TFRC	TT8MG4S	Strong	Altered Expression	[116]
TGFB2	TTI0KH6	Strong	Biomarker	[117]
TH	TTUHP71	Strong	Altered Expression	[118]
TNFSF10	TTA5MS9	Strong	Biomarker	[119]
TOP2A	TTCGY2K	Strong	Biomarker	[40]
TRPV6	TTBK14N	Strong	Biomarker	[40]
TTK	TTP7EGM	Strong	Biomarker	[40]
UCP2	TTSC2YM	Strong	Altered Expression	[120]
ZNF217	TTY3BRA	Strong	Biomarker	[121]
CHM	TTOA18V	Definitive	Biomarker	[122]
GNRHR	TT8R70G	Definitive	Biomarker	[123]

This Disease Is Related to 3 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC5A11	DT2CAPQ	moderate	Biomarker	[124]
SLC5A3	DT8ACN1	moderate	Altered Expression	[124]
ABCB6	DTF9Y2V	Strong	Biomarker	[40]

This Disease Is Related to 18 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
BCO1	DE6BOK3	Limited	Genetic Variation	[125]
AKR1C1	DE7P2FB	moderate	Biomarker	[126]
CHST3	DEQIZP2	moderate	Biomarker	[21]
NNMT	DECVGJ3	moderate	Altered Expression	[127]
PON2	DEHJU7E	moderate	Genetic Variation	[128]
AKR1C2	DEOY5ZM	Strong	Biomarker	[126]
BAAT	DERA3OF	Strong	Biomarker	[129]
CYP2R1	DEBIHM3	Strong	Genetic Variation	[130]
CYP3A7	DERD86B	Strong	Altered Expression	[131]
DHCR7	DEL7GFA	Strong	Genetic Variation	[132]
DHRS9	DEGTU5I	Strong	Altered Expression	[133]
EPHX1	DELB4KP	Strong	Posttranslational Modification	[134]
FADS1	DE05S8C	Strong	Biomarker	[96]
GPT	DER5HFI	Strong	Altered Expression	[135]
HSD3B1	DERDQWN	Strong	Genetic Variation	[136]
HSD3B2	DEN0GVQ	Strong	Biomarker	[137]
NMNAT3	DERBKPU	Strong	Biomarker	[40]
SULT2A1	DE0P6LK	Strong	Biomarker	[138]

This Disease Is Related to 261 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADAMTS19	OTEG5Q2G	Limited	Biomarker	[139]
APOC1	OTA58CED	Limited	Genetic Variation	[33]
ATP5F1B	OTLFZUQK	Limited	Biomarker	[140]
DMAP1	OT1ZMQTU	Limited	Posttranslational Modification	[141]
MAP3K15	OT1E21HI	Limited	Biomarker	[142]
NANS	OTMQ2FUH	Limited	Genetic Variation	[143]
SLPI	OTUNFUU8	Limited	Biomarker	[144]
SVEP1	OTOBICRD	Limited	Genetic Variation	[141]
TSPAN31	OT8WQ83R	Limited	Genetic Variation	[143]
ADAMTS9	OTV3Q0DS	moderate	Altered Expression	[107]
ADIPOR2	OT2HDTL8	moderate	Altered Expression	[145]
AFM	OTPOR8IO	moderate	Biomarker	[146]
BCAR3	OTPJ17M8	moderate	Biomarker	[147]
CBX2	OTOQ5WS4	moderate	Biomarker	[142]
CFAP97	OT0RSQO4	moderate	Biomarker	[129]
COPA	OTZ1DTXU	moderate	Biomarker	[148]
CTRL	OTB6NA5O	moderate	Biomarker	[149]
FBLN1	OT5MHHOP	moderate	Biomarker	[150]
FLVCR1	OT9XCFOC	moderate	Biomarker	[151]
GAB1	OTQKE6V4	moderate	Altered Expression	[152]
GC	OTWS63BY	moderate	Biomarker	[153]
GREM2	OTE91EWT	moderate	Altered Expression	[154]
HAS1	OTJIAG1W	moderate	Biomarker	[155]
HAS2	OTTD3PAL	moderate	Biomarker	[155]
HAS3	OTPM8IL8	moderate	Biomarker	[155]
IGF2BP2	OT4ZSEEE	moderate	Altered Expression	[8]
IMMP2L	OT9WGAFD	moderate	Biomarker	[8]
INSL5	OTLUI3PV	moderate	Altered Expression	[156]
INSL6	OTF8OJQC	moderate	Altered Expression	[156]
LEAP2	OTUOPIS5	moderate	Altered Expression	[157]
MKRN3	OTAFO4YR	moderate	Genetic Variation	[158]
MPG	OTAHW80B	moderate	Biomarker	[159]
PNN	OT0HXICH	moderate	Biomarker	[160]
PRDX3	OTLB2WEU	moderate	Altered Expression	[161]
PRPF31	OTSJ0Z1Y	moderate	Biomarker	[162]
RARRES2	OT1BJE8K	moderate	Altered Expression	[163]
RPS26	OTBYTA6A	moderate	Biomarker	[164]
SERBP1	OTZVSU0X	moderate	Altered Expression	[8]
SPPL3	OT2HLJF6	moderate	Biomarker	[8]
STK26	OTW4QE0D	moderate	Biomarker	[165]
ACACA	OT5CQPZY	Strong	Biomarker	[166]
ACAN	OTUOCW8K	Strong	Biomarker	[167]
ACTA1	OTOVGLPG	Strong	Genetic Variation	[73]
ADA2	OTGCV24S	Strong	Genetic Variation	[168]
ADAMTS7	OTVKZ1DV	Strong	Biomarker	[40]
ADARB1	OTGKSZEV	Strong	Biomarker	[40]
ADIPOR1	OT65ZFZN	Strong	Altered Expression	[169]
AKAP8	OTK3EQAI	Strong	Biomarker	[170]
ALDH1A3	OT1C9NKQ	Strong	Altered Expression	[171]
ANGPTL1	OTXIN6V5	Strong	Altered Expression	[172]
ANGPTL2	OTB6JG41	Strong	Altered Expression	[173]
ANGPTL6	OTOQ5W67	Strong	Altered Expression	[174]
ANGPTL8	OTQFINCD	Strong	Altered Expression	[175]
ANLN	OTXJY54C	Strong	Biomarker	[40]
AOPEP	OT0MMANL	Strong	Genetic Variation	[7]
APPL1	OT8VR95S	Strong	Biomarker	[176]
AQP8	OT99JKME	Strong	Altered Expression	[36]
ARHGAP23	OTX1RY0T	Strong	Biomarker	[40]
ARHGAP30	OTESZLFG	Strong	Biomarker	[40]
ARHGAP9	OTJNHX96	Strong	Biomarker	[88]
ARID1B	OTILK3Q7	Strong	Genetic Variation	[177]
ARID4B	OTYLPILE	Strong	Biomarker	[178]
ARSD	OTAHW9M8	Strong	Biomarker	[179]
ASPM	OTKXQMNA	Strong	Biomarker	[40]
ATAD1	OTJ02XFL	Strong	Genetic Variation	[180]
ATF1	OT251CI0	Strong	Biomarker	[40]
BBOF1	OT88DXU7	Strong	Biomarker	[40]
BGLAP	OTK1YLWQ	Strong	Altered Expression	[181]
BHMT	OTYB6PXZ	Strong	Biomarker	[182]
BLOC1S3	OTNRFFLW	Strong	Biomarker	[40]
BMPR1A	OTQOA4ZH	Strong	Altered Expression	[43]
C1QL3	OT4TZH3J	Strong	Biomarker	[183]
C1QTNF12	OTFAIQHR	Strong	Biomarker	[183]
C1QTNF3	OTOJMWW0	Strong	Altered Expression	[184]
CAMK2D	OTJ5XLVU	Strong	Biomarker	[40]
CAPN5	OTQ8QM7K	Strong	Biomarker	[185]
CARMIL3	OT4ZN0K3	Strong	Biomarker	[40]
CCDC91	OTLZNXDL	Strong	Genetic Variation	[112]
CDC6	OTX93FE7	Strong	Biomarker	[40]
CDH15	OTJ1TO02	Strong	Biomarker	[40]
CEP55	OTGSG2PA	Strong	Biomarker	[40]
CKS2	OTPTMHIV	Strong	Biomarker	[40]
CMTR2	OT82FBWS	Strong	Biomarker	[40]
CNTROB	OTR7C7NR	Strong	Biomarker	[40]
CPT2	OTIN6G20	Strong	Biomarker	[186]
CRB1	OTXYUNG0	Strong	Genetic Variation	[112]
CYC1	OT0962IM	Strong	Biomarker	[187]
DACT3	OTSNQ55G	Strong	Biomarker	[40]
DBP	OTE0W7LN	Strong	Biomarker	[188]
DCBLD2	OTB71I02	Strong	Biomarker	[40]
DDX54	OTVOJU6G	Strong	Biomarker	[40]
DESI1	OTFNIW98	Strong	Biomarker	[189]
DHRS11	OTU3J0ZL	Strong	Altered Expression	[75]
DOCK1	OTCFV3ON	Strong	Biomarker	[190]
DRAM2	OTBOCZH8	Strong	Altered Expression	[191]
DSCC1	OTPUVLZT	Strong	Biomarker	[192]
ECI1	OTRQTK84	Strong	Biomarker	[193]
EGR3	OTGPJIRA	Strong	Genetic Variation	[71]
ELAVL3	OTI2VI8B	Strong	Biomarker	[40]
ELMO1	OTY2ORXK	Strong	Biomarker	[190]
EMSY	OTBQ3KQE	Strong	Biomarker	[40]
ENHO	OT91QASK	Strong	Biomarker	[194]
ERRFI1	OT7VZ2IZ	Strong	Biomarker	[40]
FBN3	OTEWLXTH	Strong	Genetic Variation	[195]
FBRS	OTUVH446	Strong	Genetic Variation	[196]
FBXO44	OTEUEUTZ	Strong	Biomarker	[40]
FBXO8	OTZNGJGW	Strong	Genetic Variation	[196]
FEM1A	OT0BGJQS	Strong	Genetic Variation	[197]
FEM1B	OTFE2ELA	Strong	Genetic Variation	[197]
FLAD1	OTY8R02L	Strong	Genetic Variation	[96]
FTMT	OTIUX6XG	Strong	Biomarker	[92]
FUT7	OTJF6BSN	Strong	Biomarker	[40]
FZD3	OTIWDN78	Strong	Altered Expression	[198]
GABARAP	OTAQUX6E	Strong	Biomarker	[199]
GABRB1	OT4L2SSB	Strong	Genetic Variation	[81]
GCKR	OTSIWXGG	Strong	Genetic Variation	[200]
GDF9	OTNTVKVU	Strong	Biomarker	[201]
GNAS	OTMH8BKJ	Strong	Biomarker	[40]
GNB3	OTA6HYBA	Strong	Genetic Variation	[202]
GP1BB	OTD7XNLL	Strong	Biomarker	[40]
GPR83	OT7A2FE8	Strong	Biomarker	[203]
GPX3	OT6PK94R	Strong	Biomarker	[204]
GYS2	OTCKIUYR	Strong	Biomarker	[205]
HACD1	OTEC7EP7	Strong	Biomarker	[40]
HELLS	OTVVV668	Strong	Biomarker	[40]
HMMR	OT4M0JTZ	Strong	Biomarker	[40]
HOOK3	OT0OE8SX	Strong	Biomarker	[40]
HOXA10	OTB6GQ09	Strong	Altered Expression	[206]
IARS1	OT9WXH5N	Strong	Genetic Variation	[207]
IGFBP4	OT2HZRBD	Strong	Altered Expression	[80]
IL34	OTZ15VVK	Strong	Biomarker	[40]
INHA	OT7HWCO3	Strong	Biomarker	[208]
INHBB	OT2QLD11	Strong	Biomarker	[208]
INSIG2	OTX4VY51	Strong	Genetic Variation	[209]
INSL3	OT7KUNTE	Strong	Biomarker	[210]
IQCC	OTVNC81X	Strong	Biomarker	[40]
ISYNA1	OT49ONSE	Strong	Biomarker	[40]
ITGAX	OTOGIMHE	Strong	Altered Expression	[211]
ITGB5	OT21MF51	Strong	Biomarker	[212]
ITLN1	OT7ZLJVV	Strong	Altered Expression	[213]
JSRP1	OT1AAYWO	Strong	Biomarker	[40]
KHDRBS3	OTUG02U7	Strong	Altered Expression	[214]
KRR1	OTCMJ3K3	Strong	Genetic Variation	[215]
KRT16	OTGA0EQN	Strong	Biomarker	[6]
KRT3	OT5U1Y8L	Strong	Biomarker	[40]
LARP4	OTB10IJH	Strong	Biomarker	[40]
LHB	OT5GBOVJ	Strong	Genetic Variation	[216]
LPCAT2	OT6NTBAA	Strong	Biomarker	[40]
LPIN1	OTQ75KF2	Strong	Genetic Variation	[217]
LRATD1	OT65IL83	Strong	Biomarker	[40]
LSM5	OTCQHXK5	Strong	Biomarker	[40]
MAD2L1	OTXNGZCG	Strong	Biomarker	[40]
MAGEA11	OTLT6Q3G	Strong	Altered Expression	[218]
MANEA	OTV7L8I6	Strong	Biomarker	[219]
MAPK8IP3	OT0X8ACY	Strong	Biomarker	[40]
MAPRE1	OTCVQD60	Strong	Genetic Variation	[7]
MAPRE3	OTSCLETV	Strong	Biomarker	[40]
MCF2L2	OTOGFMIH	Strong	Biomarker	[220]
MCM2	OTGGORIQ	Strong	Biomarker	[221]
MEF2A	OTV2SF6E	Strong	Biomarker	[92]
MEP1A	OTY2Z48T	Strong	Genetic Variation	[222]
MGAT5B	OT5HP73K	Strong	Biomarker	[40]
MIOX	OTDD9G4E	Strong	Altered Expression	[223]
MMP26	OT9O89KU	Strong	Altered Expression	[224]
MOK	OTQK7M9V	Strong	Biomarker	[225]
MORN1	OTQEM4BT	Strong	Biomarker	[40]
MRO	OT5U38CP	Strong	Altered Expression	[226]
MSC	OTBRPZL5	Strong	Biomarker	[227]
MYBL1	OTBJMC2P	Strong	Biomarker	[40]
NANOS3	OTGX9IQU	Strong	Genetic Variation	[228]
NCOR1	OT04XNOU	Strong	Biomarker	[229]
NEIL2	OTV6JEON	Strong	Genetic Variation	[42]
NFIC	OTLMCUIB	Strong	Altered Expression	[230]
NOC2L	OTNT7R33	Strong	Biomarker	[231]
NOP53	OTA2YKO6	Strong	Biomarker	[40]
NPB	OT0U82T3	Strong	Biomarker	[40]
NUCB2	OTHO6JWN	Strong	Altered Expression	[169]
OR10A4	OTYYB8SY	Strong	Genetic Variation	[232]
OR2AG1	OTEITRP4	Strong	Genetic Variation	[233]
PAPPA	OTTTG9PG	Strong	Altered Expression	[234]
PAPSS2	OTDLEXPN	Strong	Genetic Variation	[235]
PDCD4	OTZ6NXUX	Strong	Altered Expression	[236]
PDLIM4	OT23LZYY	Strong	Biomarker	[40]
PEA15	OTKCKTSX	Strong	Altered Expression	[237]
PKD1	OT5ALRZ5	Strong	Biomarker	[6]
PLEKHG5	OTL0S21W	Strong	Biomarker	[40]
PLXNA2	OTNNBJMQ	Strong	Biomarker	[238]
PNPLA2	OTR3ERMR	Strong	Altered Expression	[239]
POLD3	OTEQEFQ2	Strong	Biomarker	[77]
PPARGC1A	OTHCDQ22	Strong	Biomarker	[240]
PPP1R3A	OTJL9VYP	Strong	Genetic Variation	[241]
PRKAG3	OTS1A2VE	Strong	Genetic Variation	[242]
PRKD2	OTIFSVI8	Strong	Biomarker	[40]
PROK1	OT8S7RUG	Strong	Biomarker	[243]
PTBP2	OTF4S7NE	Strong	Biomarker	[176]
PTCRA	OTQTO5QZ	Strong	Biomarker	[40]
PTRH2	OTBU39Q1	Strong	Altered Expression	[244]
PWWP2B	OT6CTWCB	Strong	Biomarker	[40]
RAB2A	OT6SK83U	Strong	Biomarker	[40]
RAB5B	OT06PN42	Strong	Genetic Variation	[245]
RACGAP1	OTQE8IEH	Strong	Biomarker	[40]
RAD50	OTYMU9G1	Strong	Genetic Variation	[215]
RAD54B	OTMWB2P2	Strong	Biomarker	[246]
RAPSN	OTGMSWDQ	Strong	Genetic Variation	[96]
RASL10B	OT0A5YKR	Strong	Biomarker	[40]
REXO1	OTZT6RAW	Strong	Biomarker	[40]
RHOG	OTJ7J1WA	Strong	Biomarker	[190]
RHPN1	OTYZ1NV8	Strong	Biomarker	[40]
RP2	OTK050I3	Strong	Biomarker	[40]
RPL3	OTX6VXLB	Strong	Genetic Variation	[247]
RPL36A	OT1LYV85	Strong	Genetic Variation	[40]
RPL37A	OTAMQLY7	Strong	Biomarker	[40]
S100A7A	OTNM8DCP	Strong	Biomarker	[40]
S100P	OTJCXNJG	Strong	Biomarker	[40]
SAP30L	OTI15CY4	Strong	Biomarker	[40]
SCNN1A	OTE2KVZV	Strong	Biomarker	[40]
SERPINA12	OTS1E6IP	Strong	Altered Expression	[248]
SERPINB2	OT72QLZB	Strong	Genetic Variation	[249]
SET	OTGYYQJO	Strong	Biomarker	[250]
SFRP5	OTLCVVSH	Strong	Biomarker	[251]
SFTPC	OTIZJD09	Strong	Biomarker	[40]
SFXN1	OTL66767	Strong	Genetic Variation	[252]
SGK3	OTQ6QO99	Strong	Altered Expression	[253]
SLC2A4RG	OTW3LX8D	Strong	Biomarker	[254]
SLC35G1	OTKZUA8O	Strong	Biomarker	[189]
SORCS1	OTP8PAKU	Strong	Genetic Variation	[255]
SOX15	OTTB37I1	Strong	Biomarker	[40]
SPATA21	OTGTXLP9	Strong	Biomarker	[40]
SPTBN4	OTAJAVP9	Strong	Biomarker	[40]
SRSF10	OTY6IJ11	Strong	Biomarker	[40]
STUB1	OTSUYI9A	Strong	Genetic Variation	[256]
TAB1	OTPM6F85	Strong	Biomarker	[40]
TAB2	OTPZK76F	Strong	Biomarker	[12]
TAC3	OTOJGM38	Strong	Altered Expression	[25]
TADA1	OTV9RKSL	Strong	Genetic Variation	[168]
TAS2R13	OTSTOX5G	Strong	Genetic Variation	[257]
TBC1D4	OTK66C40	Strong	Biomarker	[258]
TBX1	OTQLBPRA	Strong	Biomarker	[40]
TCF15	OTA6UCWC	Strong	Biomarker	[40]
TCFL5	OTJL4348	Strong	Genetic Variation	[259]
TEAD2	OTM8YMYT	Strong	Biomarker	[40]
THAP3	OTIRS3X3	Strong	Biomarker	[40]
TIMP4	OT8A68SW	Strong	Biomarker	[260]
TLE5	OTEH0BFG	Strong	Biomarker	[261]
TM4SF4	OTRI8EHN	Strong	Altered Expression	[224]
TMEFF2	OT1WZ2QO	Strong	Biomarker	[40]
TMEM120B	OTA5XMI9	Strong	Altered Expression	[262]
TMEM151A	OT110BRM	Strong	Biomarker	[40]
TMEM151B	OTTEDBUJ	Strong	Biomarker	[40]
TMEM18	OT05YQ1E	Strong	Biomarker	[263]
TMF1	OT7JY7UF	Strong	Biomarker	[40]
TNPO2	OTGHFQAV	Strong	Biomarker	[40]
TNRC6B	OTGVT0SH	Strong	Biomarker	[40]
TONSL	OTBWODM9	Strong	Biomarker	[40]
TOR2A	OT1EGCDU	Strong	Altered Expression	[264]
TOX3	OTC9NR4W	Strong	Altered Expression	[265]
TPD52	OTPKSK43	Strong	Biomarker	[6]
TPM1	OTD73X6R	Strong	Biomarker	[266]
TPM2	OTA1L0P8	Strong	Biomarker	[267]
TRIB3	OTG5OS7X	Strong	Genetic Variation	[257]
TTLL9	OT1M1SZH	Strong	Biomarker	[40]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3884).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT04852510) Amelioration of Polycystic Ovary Syndrome Related Disorders by Supplementation of Thymoquinone and Metformin. U.S. National Institutes of Health.
• [4] Follicular localization of growth differentiation factor 8 and its receptors in normal and polycystic ovary syndrome ovaries.Biol Reprod. 2018 May 1;98(5):683-694. doi: 10.1093/biolre/ioy029.
• [5] Ovarian expression of alpha (1)- and beta (2)-adrenoceptors and p75 neurotrophin receptors in rats with steroid-induced polycystic ovaries.Auton Neurosci. 2005 Mar 31;118(1-2):79-87. doi: 10.1016/j.autneu.2005.01.004.
• [6] Association of genetic polymorphism of PC-1 gene (rs1044498 Lys121Gln) with insulin-resistant type 2 diabetes mellitus in Punjabi Population of Pakistan.Mol Genet Genomic Med. 2019 Aug;7(8):e775. doi: 10.1002/mgg3.775. Epub 2019 Jun 28.
• [7] Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria.PLoS Genet. 2018 Dec 19;14(12):e1007813. doi: 10.1371/journal.pgen.1007813. eCollection 2018 Dec.
• [8] The HMGA2-IMP2 Pathway Promotes Granulosa Cell Proliferation in Polycystic Ovary Syndrome.J Clin Endocrinol Metab. 2019 Apr 1;104(4):1049-1059. doi: 10.1210/jc.2018-00544.
• [9] Gremlin is a potential target for posterior capsular opacification.Cell Cycle. 2019 Aug;18(15):1714-1726. doi: 10.1080/15384101.2019.1632125. Epub 2019 Jun 24.
• [10] Comparative studies of the role of hormone-sensitive lipase and adipose triglyceride lipase in human fat cell lipolysis.Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1847-55. doi: 10.1152/ajpendo.00040.2007. Epub 2007 Feb 27.
• [11] Loss of PKB/Akt2 predisposes mice to ovarian cyst formation and increases the severity of polycystic ovary formation in vivo.Dis Model Mech. 2012 May;5(3):403-11. doi: 10.1242/dmm.008136. Epub 2012 Jan 24.
• [12] Differential gene expression in granulosa cells from polycystic ovary syndrome patients with and without insulin resistance: identification of susceptibility gene sets through network analysis.J Clin Endocrinol Metab. 2012 Oct;97(10):E2016-21. doi: 10.1210/jc.2011-3441. Epub 2012 Aug 17.
• [13] Effects of omega-3 polyunsaturated fatty acids on steroidogenesis and cellular development in PCOS rats.Food Funct. 2019 May 22;10(5):2504-2514. doi: 10.1039/c8fo02319k.
• [14] Steroidogenic regulatory factor FOS is underexpressed in polycystic ovary syndrome (PCOS) adipose tissue and genetically associated with PCOS susceptibility.J Clin Endocrinol Metab. 2012 Sep;97(9):E1750-7. doi: 10.1210/jc.2011-2153. Epub 2012 Jun 21.
• [15] Amelioration by quercetin of insulin resistance and uterine GLUT4 and ER gene expression in rats with polycystic ovary syndrome (PCOS).Reprod Fertil Dev. 2019 Jan;31(2):315-323. doi: 10.1071/RD18222.
• [16] Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic ovary syndrome (PCOS) model through anti-androgenic mechanism.Pharm Biol. 2017 Dec;55(1):242-251. doi: 10.1080/13880209.2016.1258425.
• [17] Expression of the anti-Mullerian hormone, kisspeptin 1, and kisspeptin 1 receptor in polycystic ovary syndrome and controlled ovarian stimulation rat models.Bosn J Basic Med Sci. 2020 Feb 5;20(1):37-43. doi: 10.17305/bjbms.2019.4281.
• [18] Impact of primary posterior capsulorhexis on regeneratory after-cataract and YAG laser rates with an acrylic micro-incision intraocular lens with plate haptics: 1-year and 3-year results.Acta Ophthalmol. 2019 Dec;97(8):e1130-e1135. doi: 10.1111/aos.14156. Epub 2019 Jun 13.
• [19] Melanocortin 3 receptor gene polymorphism is associated with polycystic ovary syndrome in Turkish population.Gynecol Endocrinol. 2019 Aug;35(8):685-690. doi: 10.1080/09513590.2019.1576614. Epub 2019 Feb 20.
• [20] Variation in the perilipin gene (PLIN) affects glucose and lipid metabolism in non-Hispanic white women with and without polycystic ovary syndrome.Diabetes Res Clin Pract. 2009 Dec;86(3):186-92. doi: 10.1016/j.diabres.2009.09.002. Epub 2009 Sep 25.
• [21] Effect of resistin on estradiol and progesterone secretion from human luteinized granulosa cells in culture.Syst Biol Reprod Med. 2019 Oct;65(5):350-356. doi: 10.1080/19396368.2019.1615151. Epub 2019 May 17.
• [22] Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial.J Assist Reprod Genet. 2019 Aug;36(8):1701-1712. doi: 10.1007/s10815-019-01461-6. Epub 2019 Jul 21.
• [23] The regulation and signalling of anti-Mllerian hormone in human granulosa cells: relevance to polycystic ovary syndrome.Hum Reprod. 2019 Dec 1;34(12):2467-2479. doi: 10.1093/humrep/dez214.
• [24] Adipose Insulin Resistance in Normal-Weight Women With Polycystic Ovary Syndrome.J Clin Endocrinol Metab. 2019 Jun 1;104(6):2171-2183. doi: 10.1210/jc.2018-02086.
• [25] Altered expression of the kisspeptin/KISS1R and neurokinin B/NK3R systems in mural granulosa and cumulus cells of patients with polycystic ovarian syndrome.J Assist Reprod Genet. 2019 Jan;36(1):113-120. doi: 10.1007/s10815-018-1338-7. Epub 2018 Oct 31.
• [26] TWEAK and monocyte to HDL ratio as a predictor of metabolic syndrome in patients with polycystic ovary syndrome.Gynecol Endocrinol. 2019 Jan;35(1):66-71. doi: 10.1080/09513590.2018.1490401. Epub 2018 Sep 21.
• [27] Variants in the ACVR1 gene are associated with AMH levels in women with polycystic ovary syndrome.Hum Reprod. 2009 Jan;24(1):241-9. doi: 10.1093/humrep/den353. Epub 2008 Oct 14.
• [28] Expression of inhibin/activin system messenger ribonucleic acids and proteins in ovarian follicles from women with polycystic ovarian syndrome.J Clin Endocrinol Metab. 1994 Nov;79(5):1434-9. doi: 10.1210/jcem.79.5.7962340.
• [29] Association between 2-adrenoceptor (ADRB2) haplotypes and insulin resistance in PCOS.Clin Endocrinol (Oxf). 2013 Apr;78(4):600-6. doi: 10.1111/cen.12019.
• [30] Acupuncture and exercise restore adipose tissue expression of sympathetic markers and improve ovarian morphology in rats with dihydrotestosterone-induced PCOS.Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R1124-31. doi: 10.1152/ajpregu.90947.2008. Epub 2009 Jan 21.
• [31] Aldose reductase inhibition enhances lens regeneration in mice.Chem Biol Interact. 2019 Jul 1;307:58-62. doi: 10.1016/j.cbi.2019.04.021. Epub 2019 Apr 23.
• [32] Relationship between adipocytokines and angiotensin converting enzyme gene insertion/deletion polymorphism in lean women with and without polycystic ovary syndrome.Gynecol Endocrinol. 2020 Jun;36(6):496-500. doi: 10.1080/09513590.2019.1695248. Epub 2019 Dec 9.
• [33] Effects of apoC1 genotypes on the hormonal levels, metabolic profile and PAF-AH activity in Chinese women with polycystic ovary syndrome.Lipids Health Dis. 2018 Apr 10;17(1):77. doi: 10.1186/s12944-018-0725-5.
• [34] Adropin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with lipoprotein lipid profiles.Gynecol Endocrinol. 2018 Feb;34(2):153-156. doi: 10.1080/09513590.2017.1379498. Epub 2017 Sep 22.
• [35] Aquaglyceroporin-7 overexpression in women with the polycystic ovary syndrome.Gynecol Obstet Invest. 2013;75(2):126-31. doi: 10.1159/000345069. Epub 2012 Dec 7.
• [36] AQP8 and AQP9 expression in patients with polycystic ovary syndrome and its association with in vitro fertilization-embryo transfer outcomes.Exp Ther Med. 2019 Jul;18(1):755-760. doi: 10.3892/etm.2019.7592. Epub 2019 May 20.
• [37] Activating transcriptional factor 4 correlated with obesity and insulin resistance in polycystic ovary syndrome.Gynecol Endocrinol. 2019 Apr;35(4):351-355. doi: 10.1080/09513590.2018.1527307. Epub 2018 Nov 1.
• [38] Association between circulating zinc-2-glycoprotein levels and the different phenotypes of polycystic ovary syndrome.Endocr J. 2020 Mar 28;67(3):249-255. doi: 10.1507/endocrj.EJ18-0506. Epub 2019 Nov 21.
• [39] Altered expression of Bcl-2 and Bax in follicles within dehydroepiandrosterone-induced polycystic ovaries in rats.Cell Biol Int. 2011 May;35(5):423-9. doi: 10.1042/CBI20100542.
• [40] Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles.J Clin Endocrinol Metab. 2011 Jun;96(6):1737-46. doi: 10.1210/jc.2010-2600. Epub 2011 Mar 16.
• [41] The influencing mechanism of mTOR signal pathway mediated by mitofusin-2 in development of follicle.Eur Rev Med Pharmacol Sci. 2018 Apr;22(8):2212-2217. doi: 10.26355/eurrev_201804_14806.
• [42] Phenotype and Tissue Expression as a Function of Genetic Risk in Polycystic Ovary Syndrome.PLoS One. 2017 Jan 9;12(1):e0168870. doi: 10.1371/journal.pone.0168870. eCollection 2017.
• [43] BMP system expression in GCs from polycystic ovary syndrome women and the in vitro effects of BMP4, BMP6, and BMP7 on GC steroidogenesis.Eur J Endocrinol. 2013 Feb 20;168(3):437-44. doi: 10.1530/EJE-12-0891. Print 2013 Mar.
• [44] Apoptotic biomarkers in cumulus cells in relation to embryo quality in polycystic ovary syndrome.Arch Gynecol Obstet. 2017 Dec;296(6):1219-1227. doi: 10.1007/s00404-017-4523-5. Epub 2017 Oct 7.
• [45] Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome.Fertil Steril. 2018 Mar;109(3):508-515. doi: 10.1016/j.fertnstert.2017.11.017. Epub 2018 Feb 7.
• [46] Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome.Nat Genet. 2012 Sep;44(9):1020-5. doi: 10.1038/ng.2384. Epub 2012 Aug 12.
• [47] RNA interference mediated pten knock-down inhibit the formation of polycystic ovary.Mol Cell Biochem. 2013 Aug;380(1-2):195-202. doi: 10.1007/s11010-013-1673-z. Epub 2013 May 19.
• [48] High level of C-type natriuretic peptide induced by hyperandrogen-mediated anovulation in polycystic ovary syndrome mice.Clin Sci (Lond). 2018 Apr 6;132(7):759-776. doi: 10.1042/CS20171394. Print 2018 Apr 16.
• [49] The efficacy of Tung's acupuncture for sex hormones in polycystic ovary syndrome: A randomized controlled trial.Complement Ther Med. 2019 Jun;44:182-188. doi: 10.1016/j.ctim.2019.04.016. Epub 2019 Apr 24.
• [50] Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.Exp Clin Endocrinol Diabetes. 2008 Mar;116(3):143-7. doi: 10.1055/s-2007-992118.
• [51] Cardiotrophin-1 as a new metabolic biomarker in women with PCOS.Gynecol Endocrinol. 2018 Sep;34(9):781-783. doi: 10.1080/09513590.2018.1457637. Epub 2018 Mar 30.
• [52] Traditional Medicine (Mahuang-Tang) Improves Ovarian Dysfunction and the Regulation of Steroidogenic Genes in Letrozole-Induced PCOS Rats.J Ethnopharmacol. 2020 Feb 10;248:112300. doi: 10.1016/j.jep.2019.112300. Epub 2019 Oct 10.
• [53] Polycystic ovarian disease and congenital and late-onset adrenal hyperplasia.Endocrinol Metab Clin North Am. 1988 Dec;17(4):637-48.
• [54] Competing Factors Link to Bone Health in Polycystic Ovary Syndrome: Chronic Low-Grade Inflammation Takes a Toll.Sci Rep. 2017 Jun 13;7(1):3432. doi: 10.1038/s41598-017-03685-x.
• [55] Harnessing expression data to identify novel candidate genes in polycystic ovary syndrome.PLoS One. 2011;6(5):e20120. doi: 10.1371/journal.pone.0020120. Epub 2011 May 17.
• [56] Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome.J Clin Endocrinol Metab. 2020 Jan 1;105(1):136-51. doi: 10.1210/clinem/dgz028.
• [57] Altered endothelin expression in granulosa-lutein cells of women with polycystic ovary syndrome.Life Sci. 2012 Oct 15;91(13-14):703-9. doi: 10.1016/j.lfs.2012.06.006. Epub 2012 Jun 19.
• [58] Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS).Life Sci. 2019 Jul 1;228:167-175. doi: 10.1016/j.lfs.2019.04.046. Epub 2019 Apr 25.
• [59] Erythropoietin-producing hepatocellular A7 triggering ovulation indicates a potential beneficial role for polycystic ovary syndrome.EBioMedicine. 2018 Oct;36:539-552. doi: 10.1016/j.ebiom.2018.09.046. Epub 2018 Oct 3.
• [60] Novel Serum Biomarkers Detected by Protein Array in Polycystic Ovary Syndrome with Low Progesterone Level.Cell Physiol Biochem. 2018;46(6):2297-2310. doi: 10.1159/000489619. Epub 2018 May 3.
• [61] Androgen levels and metabolic parameters are associated with a genetic variant of F13A1 in women with polycystic ovary syndrome.Gene. 2012 Aug 1;504(1):133-9. doi: 10.1016/j.gene.2012.04.050. Epub 2012 Apr 28.
• [62] Association of IL-1, IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome.Inflamm Res. 2017 Jul;66(7):621-636. doi: 10.1007/s00011-017-1045-3. Epub 2017 Apr 12.
• [63] FABP4: a novel candidate gene for polycystic ovary syndrome.Endocrine. 2009 Dec;36(3):392-6. doi: 10.1007/s12020-009-9228-5. Epub 2009 Oct 21.
• [64] Role of Insulin-like growth factors in initiation of follicle growth in normal and polycystic human ovaries.J Clin Endocrinol Metab. 2013 Aug;98(8):3298-305. doi: 10.1210/jc.2013-1378. Epub 2013 Jun 7.
• [65] Serum concentrations of fibroblast growth factors 19 and 21 in women with gestational diabetes mellitus: association with insulin resistance, adiponectin, and polycystic ovary syndrome history.PLoS One. 2013 Nov 19;8(11):e81190. doi: 10.1371/journal.pone.0081190. eCollection 2013.
• [66] Apolipoprotein A-IV as a novel gene associated with polycystic ovary syndrome.Int J Mol Med. 2013 Mar;31(3):707-16. doi: 10.3892/ijmm.2013.1250. Epub 2013 Jan 17.
• [67] Expression of FKBP52 in the ovaries of PCOS rats.Int J Mol Med. 2019 Feb;43(2):868-878. doi: 10.3892/ijmm.2018.3998. Epub 2018 Nov 26.
• [68] Liuwei Dihuang Pills alleviate the polycystic ovary syndrome with improved insulin sensitivity through PI3K/Akt signaling pathway.J Ethnopharmacol. 2020 Mar 25;250:111965. doi: 10.1016/j.jep.2019.111965. Epub 2019 Jun 8.
• [69] The hepatic glycogen storage diseases--problems beyond childhood.J Inherit Metab Dis. 1995;18(4):462-72. doi: 10.1007/BF00710057.
• [70] Association of -604G/A and -501A/C Ghrelin and Obestatin Prepropeptide Gene Polymorphisms with Polycystic Ovary Syndrome.Biochem Genet. 2018 Apr;56(1-2):116-127. doi: 10.1007/s10528-017-9834-5. Epub 2017 Dec 11.
• [71] DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.Endocr Pract. 2018 Jan;24(1):69-77. doi: 10.4158/EP-2017-0027. Epub 2017 Nov 16.
• [72] A functional GNAQ promoter haplotype is associated with altered Gq expression and with insulin resistance and obesity in women with polycystic ovary syndrome.Pharmacogenet Genomics. 2010 Aug;20(8):476-84. doi: 10.1097/FPC.0b013e32833b7497.
• [73] Association of vitamin D receptor gene polymorphisms with polycystic ovary syndrome among Indian women.Indian J Med Res. 2015 Sep;142(3):276-85. doi: 10.4103/0971-5916.166587.
• [74] PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer.Oncotarget. 2017 May 13;8(41):69520-69526. doi: 10.18632/oncotarget.17846. eCollection 2017 Sep 19.
• [75] The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome.J Clin Endocrinol Metab. 2001 Dec;86(12):5925-33. doi: 10.1210/jcem.86.12.8088.
• [76] Alterations of folliculogenesis in women with polycystic ovary syndrome.J Steroid Biochem Mol Biol. 2011 Mar;124(1-2):58-64. doi: 10.1016/j.jsbmb.2011.01.008. Epub 2011 Jan 22.
• [77] Microarray analysis of obese women with polycystic ovary syndrome for key gene screening, key pathway identification and drug prediction.Gene. 2018 Jun 30;661:85-94. doi: 10.1016/j.gene.2018.03.079. Epub 2018 Mar 28.
• [78] Association of genetic variants of insulin degrading enzyme with metabolic features in women with polycystic ovary syndrome.Fertil Steril. 2008 Aug;90(2):378-84. doi: 10.1016/j.fertnstert.2007.06.016. Epub 2007 Oct 22.
• [79] Fasting as possible complementary approach for polycystic ovary syndrome: Hope or hype?.Med Hypotheses. 2017 Aug;105:1-3. doi: 10.1016/j.mehy.2017.06.013. Epub 2017 Jun 23.
• [80] mRNA expression pattern of insulin-like growth factor components of granulosa cells and cumulus cells in women with and without polycystic ovary syndrome according to oocyte maturity.Fertil Steril. 2010 Nov;94(6):2417-20. doi: 10.1016/j.fertnstert.2010.03.053. Epub 2010 May 8.
• [81] High Genetic Risk Scores of ASIC2, MACROD2, CHRM3, and C2orf83 Genetic Variants Associated with Polycystic Ovary Syndrome Impair Insulin Sensitivity and Interact with Energy Intake in Korean Women.Gynecol Obstet Invest. 2019;84(3):225-236. doi: 10.1159/000493131. Epub 2018 Oct 19.
• [82] Gene Expression in Granulosa Cells From Small Antral Follicles From Women With or Without Polycystic Ovaries.J Clin Endocrinol Metab. 2019 Dec 1;104(12):6182-6192. doi: 10.1210/jc.2019-00780.
• [83] Regulation of androgen receptor signaling by ubiquitination during folliculogenesis and its possible dysregulation in polycystic ovarian syndrome.Sci Rep. 2017 Aug 31;7(1):10272. doi: 10.1038/s41598-017-09880-0.
• [84] Serum Prostate-Specific Antigen Level in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.Horm Metab Res. 2019 Apr;51(4):230-242. doi: 10.1055/a-0863-5779. Epub 2019 Apr 25.
• [85] Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women.J Ovarian Res. 2018 May 10;11(1):38. doi: 10.1186/s13048-018-0411-2.
• [86] The influence of the rs1137101 genotypes of leptin receptor gene on the demographic and metabolic profile of normal Saudi females and those suffering from polycystic ovarian syndrome.BMC Womens Health. 2019 Jan 11;19(1):10. doi: 10.1186/s12905-018-0706-x.
• [87] Decreased expression of LIF mRNA in patients withmyoma uteri.J Cell Biochem. 2019 Mar;120(3):3423-3427. doi: 10.1002/jcb.27613. Epub 2018 Sep 22.
• [88] Pathway and network-based analysis of genome-wide association studies and RT-PCR validation in polycystic ovary syndrome.Int J Mol Med. 2017 Nov;40(5):1385-1396. doi: 10.3892/ijmm.2017.3146. Epub 2017 Sep 20.
• [89] Functional microarray analysis of differentially expressed genes in granulosa cells from women with polycystic ovary syndrome related to MAPK/ERK signaling.Sci Rep. 2015 Oct 13;5:14994. doi: 10.1038/srep14994.
• [90] MC4R variants rs12970134 and rs17782313 are associated with obese polycystic ovary syndrome patients in the Western region of Saudi Arabia.BMC Med Genet. 2019 Aug 20;20(1):144. doi: 10.1186/s12881-019-0876-x.
• [91] The expression of the miR-25/93/106b family of micro-RNAs in the adipose tissue of women with polycystic ovary syndrome.J Clin Endocrinol Metab. 2014 Dec;99(12):E2754-61. doi: 10.1210/jc.2013-4435.
• [92] Metformin augments the levels of molecules that regulate the expression of the insulin-dependent glucose transporter GLUT4 in the endometria of hyperinsulinemic PCOS patients.Hum Reprod. 2013 Aug;28(8):2235-44. doi: 10.1093/humrep/det116. Epub 2013 Apr 17.
• [93] Metformin treatment alleviates polycystic ovary syndrome by decreasing the expression of MMP-2 and MMP-9 via H19/miR-29b-3p and AKT/mTOR/autophagy signaling pathways.J Cell Physiol. 2019 Nov;234(11):19964-19976. doi: 10.1002/jcp.28594. Epub 2019 Apr 15.
• [94] Major determinants of circulating myostatin in polycystic ovary syndrome.Exp Ther Med. 2019 Feb;17(2):1383-1389. doi: 10.3892/etm.2018.7080. Epub 2018 Dec 10.
• [95] Genetic polymorphisms of melatonin receptors 1A and 1B may result in disordered lipid metabolism in obese patients with polycystic ovary syndrome.Mol Med Rep. 2019 Mar;19(3):2220-2230. doi: 10.3892/mmr.2019.9872. Epub 2019 Jan 17.
• [96] FADS1-FADS2 gene cluster confers risk to polycystic ovary syndrome.Sci Rep. 2016 Feb 16;6:21195. doi: 10.1038/srep21195.
• [97] Evaluation of steroid receptors, coregulators, and molecules associated with uterine receptivity in secretory endometria from untreated women with polycystic ovary syndrome.Fertil Steril. 2006 Apr;85(4):1017-26. doi: 10.1016/j.fertnstert.2005.09.053. Epub 2006 Mar 9.
• [98] PDE8A genetic variation, polycystic ovary syndrome and androgen levels in women.Mol Hum Reprod. 2009 Aug;15(8):459-69. doi: 10.1093/molehr/gap035. Epub 2009 May 29.
• [99] Defective insulin signaling and the protective effects of dimethyldiguanide during follicular development in the ovaries of polycystic ovary syndrome.Mol Med Rep. 2017 Dec;16(6):8164-8170. doi: 10.3892/mmr.2017.7678. Epub 2017 Sep 29.
• [100] Polymorphisms in the TFAM and PGC1- genes and their association with polycystic ovary syndrome among South Indian women.Gene. 2018 Jan 30;641:129-136. doi: 10.1016/j.gene.2017.10.010. Epub 2017 Oct 10.
• [101] Pressure pain threshold and -endorphins plasma level are higher in lean polycystic ovary syndrome women.Minerva Endocrinol. 2017 Dec;42(4):297-305. doi: 10.23736/S0391-1977.16.02494-9. Epub 2016 Sep 7.
• [102] Peroxiredoxin 4 levels in patients with PCOS and/or obesity.J Gynecol Obstet Hum Reprod. 2019 Nov;48(9):739-743. doi: 10.1016/j.jogoh.2019.04.002. Epub 2019 Apr 11.
• [103] Mechanisms behind lipolytic catecholamine resistance of subcutaneous fat cells in the polycystic ovarian syndrome.J Clin Endocrinol Metab. 2003 May;88(5):2269-73. doi: 10.1210/jc.2002-021573.
• [104] Association between prolactin receptor expression and proliferation in the endometrium of obese women with polycystic ovary syndrome.Gynecol Endocrinol. 2020 Mar;36(3):226-232. doi: 10.1080/09513590.2019.1650343. Epub 2019 Aug 7.
• [105] Androgen Receptor Coregulator CTBP1-AS Is Associated With Polycystic Ovary Syndrome in Chinese Women: A Preliminary Study.Reprod Sci. 2015 Jul;22(7):829-37. doi: 10.1177/1933719114565037. Epub 2014 Dec 31.
• [106] Hormonal alterations in PCOS and its influence on bone metabolism.J Endocrinol. 2017 Feb;232(2):R99-R113. doi: 10.1530/JOE-16-0405. Epub 2016 Nov 28.
• [107] Abnormal expressions of ADAMTS-1, ADAMTS-9 and progesterone receptors are associated with lower oocyte maturation in women with polycystic ovary syndrome.Arch Gynecol Obstet. 2019 Jan;299(1):277-286. doi: 10.1007/s00404-018-4967-2. Epub 2018 Nov 16.
• [108] Elevated circulating levels of secreted frizzled-related protein 4 in relation to insulin resistance and androgens in women with polycystic ovary syndrome.J Endocrinol Invest. 2020 Mar;43(3):305-313. doi: 10.1007/s40618-019-01108-4. Epub 2019 Sep 5.
• [109] Genetic variations in the 3'-untranslated region of SLC18A2 are associated with serum FSH concentration in polycystic ovary syndrome patients and regulate gene expression in vitro.Hum Reprod. 2016 Sep;31(9):2150-7. doi: 10.1093/humrep/dew162. Epub 2016 Jun 28.
• [110] Genotype/phenotype correlation in glycogen storage disease type 1b: a multicentre study and review of the literature.Eur J Pediatr. 2005 Aug;164(8):501-8. doi: 10.1007/s00431-005-1657-4. Epub 2005 May 19.
• [111] The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. Basic Clin Pharmacol Toxicol. 2018 Feb;122(2):239-244.
• [112] Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations.Nat Commun. 2015 Aug 18;6:7502. doi: 10.1038/ncomms8502.
• [113] Evaluating reported candidate gene associations with polycystic ovary syndrome.Fertil Steril. 2013 May;99(6):1774-8. doi: 10.1016/j.fertnstert.2012.12.033. Epub 2013 Jan 30.
• [114] In silico and functional studies reveal novel loss-of-function variants of SRD5A2, but no variants explaining excess 5-reductase activity.J Steroid Biochem Mol Biol. 2019 Jun;190:263-272. doi: 10.1016/j.jsbmb.2019.01.017. Epub 2019 Jan 28.
• [115] Association between single nucleotide polymorphisms of sterol regulatory element binding protein-2 and liver X receptor gene and risk of polycystic ovary syndrome in a Chinese Han population.Cell Biochem Biophys. 2014 Nov;70(2):1421-6. doi: 10.1007/s12013-014-0075-5.
• [116] Iron metabolism and the polycystic ovary syndrome.Trends Endocrinol Metab. 2012 Oct;23(10):509-15. doi: 10.1016/j.tem.2012.04.003. Epub 2012 May 10.
• [117] Aspirin inhibits TGF2-induced epithelial to mesenchymal transition of lens epithelial cells: selective acetylation of K56 and K122 in histone H3.Biochem J. 2020 Jan 17;477(1):75-97. doi: 10.1042/BCJ20190540.
• [118] In rats with estradiol valerate-induced polycystic ovary syndrome, the acute blockade of ovarian -adrenoreceptors improve ovulation.Reprod Biol Endocrinol. 2019 Nov 19;17(1):95. doi: 10.1186/s12958-019-0539-y.
• [119] Apoptosis and expression of protein TRAIL in granulosa cells of rats with polycystic ovarian syndrome.J Huazhong Univ Sci Technolog Med Sci. 2007 Jun;27(3):311-4. doi: 10.1007/s11596-007-0324-6.
• [120] Uncoupling protein 2 expression affects androgen synthesis in polycystic ovary syndrome.Endocrine. 2013 Jun;43(3):714-23. doi: 10.1007/s12020-012-9802-0. Epub 2012 Sep 25.
• [121] A candidate pathogenic gene, zinc finger gene 217 (ZNF217), may contribute to polycystic ovary syndrome through prostaglandin E2.Acta Obstet Gynecol Scand. 2020 Jan;99(1):119-126. doi: 10.1111/aogs.13719. Epub 2019 Oct 25.
• [122] Integrative Chinese herbal medicine therapy reduced the risk of type 2 diabetes mellitus in patients with polycystic ovary syndrome: A nationwide matched cohort study.J Ethnopharmacol. 2019 Oct 28;243:112091. doi: 10.1016/j.jep.2019.112091. Epub 2019 Jul 17.
• [123] Similarities and differences in the reproductive phenotypes of women with congenital hypogonadotrophic hypogonadism caused by GNRHR mutations and women with polycystic ovary syndrome.Hum Reprod. 2019 Jan 1;34(1):137-147. doi: 10.1093/humrep/dey339.
• [124] Human sodium/inositol cotransporter 2 (SMIT2) transports inositols but not glucose in L6 cells.Arch Biochem Biophys. 2009 Jan 15;481(2):197-201. doi: 10.1016/j.abb.2008.11.008. Epub 2008 Nov 13.
• [125] The preliminary association study of ADIPOQ, RBP4, and BCMO1 variants with polycystic ovary syndrome and with biochemical characteristics in a cohort of Polish women.Adv Med Sci. 2018 Sep;63(2):242-248. doi: 10.1016/j.advms.2018.01.002. Epub 2018 Feb 8.
• [126] The expression of sex steroid synthesis and inactivation enzymes in subcutaneous adipose tissue of PCOS patients.J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):120-6. doi: 10.1016/j.jsbmb.2012.02.003. Epub 2012 Feb 21.
• [127] N1-methylnicotinamide as a possible modulator of cardiovascular risk markers in polycystic ovary syndrome.Life Sci. 2019 Oct 15;235:116843. doi: 10.1016/j.lfs.2019.116843. Epub 2019 Sep 5.
• [128] Association of SOD2 A16V and PON2 S311C polymorphisms with polycystic ovary syndrome in Chinese women.J Endocrinol Invest. 2019 Aug;42(8):909-921. doi: 10.1007/s40618-018-0999-5. Epub 2019 Jan 3.
• [129] Polycystic ovary syndrome in adolescent girls.Pediatr Obes. 2020 Feb;15(2):e12586. doi: 10.1111/ijpo.12586. Epub 2019 Oct 30.
• [130] Association of VDBP and CYP2R1 gene polymorphisms with vitamin D status in women with polycystic ovarian syndrome: a north Indian study.Eur J Nutr. 2018 Mar;57(2):703-711. doi: 10.1007/s00394-016-1357-z. Epub 2016 Dec 23.
• [131] Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome.J Clin Endocrinol Metab. 2008 Jul;93(7):2909-12. doi: 10.1210/jc.2008-0403. Epub 2008 Apr 29.
• [132] Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome.Eur J Endocrinol. 2011 May;164(5):741-9. doi: 10.1530/EJE-11-0134. Epub 2011 Mar 9.
• [133] Comprehensive analysis of genome-wide DNA methylation across human polycystic ovary syndrome ovary granulosa cell.Oncotarget. 2016 May 10;7(19):27899-909. doi: 10.18632/oncotarget.8544.
• [134] Quantitative methylation level of the EPHX1 promoter in peripheral blood DNA is associated with polycystic ovary syndrome.PLoS One. 2014 Feb 5;9(2):e88013. doi: 10.1371/journal.pone.0088013. eCollection 2014.
• [135] Alanine Aminotransferase Is a Marker of Lipotoxicity Consequences and Hyperandrogenemia in Women with Polycystic Ovary Syndrome.Metab Syndr Relat Disord. 2017 Apr;15(3):145-152. doi: 10.1089/met.2016.0119. Epub 2017 Feb 22.
• [136] HSD3B1 gene polymorphism and female pattern hair loss in women with polycystic ovary syndrome.J Formos Med Assoc. 2019 Aug;118(8):1225-1231. doi: 10.1016/j.jfma.2019.04.013. Epub 2019 May 2.
• [137] Baicalin inhibits recruitment of GATA1 to the HSD3B2 promoter and reverses hyperandrogenism of PCOS.J Endocrinol. 2019 Jan 1:JOE-18-0678.R2. doi: 10.1530/JOE-18-0678. Online ahead of print.
• [138] Familial clustering of metabolic phenotype in brothers of women with polycystic ovary syndrome.Gynecol Endocrinol. 2019 Jul;35(7):601-603. doi: 10.1080/09513590.2019.1566451. Epub 2019 Feb 6.
• [139] Comparison of Serum A Disintegrin and Metalloproteinase with Thrombospondin Motifs-19 Levels in Different Fertility Situations: Could It Be a Serum Marker of Ovarian Function and Oocyte Pool?.Gynecol Obstet Invest. 2019;84(1):6-11. doi: 10.1159/000490665. Epub 2018 Jul 6.
• [140] ATP synthase -subunit abnormality in pancreas islets of rats with polycystic ovary syndrome and type 2 diabetes mellitus.J Huazhong Univ Sci Technolog Med Sci. 2017 Apr;37(2):210-216. doi: 10.1007/s11596-017-1717-9. Epub 2017 Apr 11.
• [141] Epigenetic and Transcriptional Alterations in Human Adipose Tissue of Polycystic Ovary Syndrome.Sci Rep. 2016 Mar 15;6:22883. doi: 10.1038/srep22883.
• [142] The transcriptional regulator CBX2 and ovarian function: A whole genome and whole transcriptome approach.Sci Rep. 2019 Nov 19;9(1):17033. doi: 10.1038/s41598-019-53370-4.
• [143] Insulin Resistance in Polycystic Ovary Syndrome Improved by Chinese Medicine Dingkun Pill (): A Randomized Controlled Clinical Trial.Chin J Integr Med. 2019 Apr;25(4):246-251. doi: 10.1007/s11655-018-2947-1. Epub 2019 Jun 25.
• [144] Induction of secretory leukocyte protease inhibitor (SLPI) in estradiol valerate (EV) induced polycystic ovary.Arch Pharm Res. 2011 Aug;34(8):1389-97. doi: 10.1007/s12272-011-0820-x. Epub 2011 Sep 11.
• [145] Role of adiponectin/peroxisome proliferator-activated receptor alpha signaling in human chorionic gonadotropin-induced estradiol synthesis in human luteinized granulosa cells.Mol Cell Endocrinol. 2019 Aug 1;493:110450. doi: 10.1016/j.mce.2019.110450. Epub 2019 May 19.
• [146] Afamin predicts gestational diabetes in polycystic ovary syndrome patients preconceptionally.Endocr Connect. 2019 May 1;8(5):616-624. doi: 10.1530/EC-19-0064.
• [147] Hyperandrogenism and Metabolic Syndrome Are Associated With Changes in Serum-Derived microRNAs in Women With Polycystic Ovary Syndrome.Front Med (Lausanne). 2019 Nov 1;6:242. doi: 10.3389/fmed.2019.00242. eCollection 2019.
• [148] The relationship between elevated serum xenin and insulin resistance in women with polycystic ovary syndrome: a case-control study.Gynecol Endocrinol. 2019 Nov;35(11):960-964. doi: 10.1080/09513590.2019.1604663. Epub 2019 Apr 23.
• [149] Age at adiposity rebound in childhood is associated with PCOS diagnosis and obesity in adulthood-longitudinal analysis of BMI data from birth to age 46 in cases of PCOS.Int J Obes (Lond). 2019 Jul;43(7):1370-1379. doi: 10.1038/s41366-019-0318-z. Epub 2019 Feb 4.
• [150] Increased fibulin-1 plasma levels in polycystic ovary syndrome (PCOS) patients: possible contribution to the link between PCOS and cardiovascular risk.J Endocrinol Invest. 2019 Jan;42(1):91-96. doi: 10.1007/s40618-018-0891-3. Epub 2018 Apr 21.
• [151] Metabolomics analysis of follicular fluid in women with ovarian endometriosis undergoing in vitro fertilization.Syst Biol Reprod Med. 2019 Feb;65(1):39-47. doi: 10.1080/19396368.2018.1478469. Epub 2018 May 28.
• [152] Characterization of GAB1 expression over the menstrual cycle in women with and without polycystic ovarian syndrome provides a new insight into its pathophysiology.J Clin Endocrinol Metab. 2014 Nov;99(11):E2162-8. doi: 10.1210/jc.2014-2128. Epub 2014 Aug 21.
• [153] Serum Vitamin D Binding Protein Level Associated with Metabolic Cardiovascular Risk Factors in Women with the Polycystic Ovary Syndrome.Horm Metab Res. 2019 Jan;51(1):54-61. doi: 10.1055/a-0759-7533. Epub 2018 Nov 8.
• [154] Gremlin-1 and gremlin-2 levels in polycystic ovary syndrome and their clinical correlations.Gynecol Endocrinol. 2019 Jul;35(7):604-607. doi: 10.1080/09513590.2019.1566452. Epub 2019 Feb 4.
• [155] Analysis of hyaluronic acid in the endometrium of women with polycystic ovary syndrome.Gynecol Endocrinol. 2019 Feb;35(2):133-137. doi: 10.1080/09513590.2018.1505844. Epub 2019 Jan 6.
• [156] Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome.J Endocrinol Invest. 2019 Mar;42(3):303-312. doi: 10.1007/s40618-018-0917-x. Epub 2018 Jun 28.
• [157] Decreased levels of liver-expressed antimicrobial peptide-2 and ghrelin are related to insulin resistance in women with polycystic ovary syndrome.Gynecol Endocrinol. 2020 Mar;36(3):222-225. doi: 10.1080/09513590.2019.1665646. Epub 2019 Sep 17.
• [158] Outcomes of Patients with Central Precocious Puberty Due to Loss-of-Function Mutations in the MKRN3 Gene after Treatment with Gonadotropin-Releasing Hormone Analog.Neuroendocrinology. 2020;110(7-8):705-713. doi: 10.1159/000504446. Epub 2019 Oct 31.
• [159] HSP90 as a novel therapeutic target for posterior capsule opacification.Exp Eye Res. 2019 Dec;189:107821. doi: 10.1016/j.exer.2019.107821. Epub 2019 Oct 4.
• [160] Effect of chlormadinone acetate versus drospirenone-containing oral contraceptives on the endocrinal features of women with polycystic ovary syndrome: Systematic review and meta-analysis of randomized clinical trials.J Gynecol Obstet Hum Reprod. 2019 Nov;48(9):763-770. doi: 10.1016/j.jogoh.2019.03.025. Epub 2019 Mar 30.
• [161] Plasma level of peroxiredoxin 3 in patients with polycystic ovarian syndrome.BMC Endocr Disord. 2019 Mar 14;19(1):32. doi: 10.1186/s12902-019-0358-3.
• [162] Polycystic Ovary Syndrome: Novel and Hub lncRNAs in the Insulin Resistance-Associated lncRNA-mRNA Network.Front Genet. 2019 Aug 22;10:772. doi: 10.3389/fgene.2019.00772. eCollection 2019.
• [163] High concentration of chemerin caused by ovarian hyperandrogenism may lead to poor IVF outcome in polycystic ovary syndrome: a pilot study.Gynecol Endocrinol. 2019 Dec;35(12):1072-1077. doi: 10.1080/09513590.2019.1622087. Epub 2019 Jun 3.
• [164] Loss of oocyte Rps26 in mice arrests oocyte growth and causes premature ovarian failure.Cell Death Dis. 2018 Nov 19;9(12):1144. doi: 10.1038/s41419-018-1196-3.
• [165] MicroRNA-486-5p inhibits ovarian granulosa cell proliferation and participates in the development of PCOS via targeting MST4.Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7217-7223. doi: 10.26355/eurrev_201909_18823.
• [166] ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome.Fertil Steril. 2019 Mar;111(3):579-587.e1. doi: 10.1016/j.fertnstert.2018.11.034.
• [167] The role of serum ADAMTS-1 and aggrecan on polycystic ovary syndrome in adolescents and younger-aged females.Arch Gynecol Obstet. 2018 Feb;297(2):487-493. doi: 10.1007/s00404-017-4578-3. Epub 2017 Oct 31.
• [168] Association of G22A and A4223C ADA1 gene polymorphisms and ADA activity with PCOS.Syst Biol Reprod Med. 2016 Jun;62(3):213-22. doi: 10.3109/19396368.2016.1143055. Epub 2016 Mar 15.
• [169] The phytoestrogen, quercetin, in serum, uterus and ovary as a potential treatment for dehydroepiandrosterone-induced polycystic ovary syndrome in the rat.Reprod Fertil Dev. 2020 Feb;32(3):313-321. doi: 10.1071/RD19072.
• [170] Role of A-kinase anchoring protein 95 in the regulation of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) in human ovarian granulosa cells.Reprod Fertil Dev. 2018 Jul;30(8):1128-1136. doi: 10.1071/RD17313.
• [171] The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis.J Biol Chem. 2003 Jul 18;278(29):26380-90. doi: 10.1074/jbc.M300688200. Epub 2003 May 6.
• [172] Aberrant expression of angiopoietin-like proteins 1 and 2 in cumulus cells is potentially associated with impaired oocyte developmental competence in polycystic ovary syndrome.Gynecol Endocrinol. 2016 Jul;32(7):557-61. doi: 10.3109/09513590.2016.1138463. Epub 2016 Feb 1.
• [173] Serum Levels of Angiopoietin-Like Protein 2 and Obestatin in Iranian Women with Polycystic Ovary Syndrome and Normal Body Mass Index.J Clin Med. 2018 Jun 22;7(7):159. doi: 10.3390/jcm7070159.
• [174] Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries.Gynecol Endocrinol. 2017 Jan;33(1):43-47. doi: 10.1080/09513590.2016.1203893. Epub 2016 Jul 16.
• [175] Serum betatrophin levels are reduced in patients with full-blown polycystic ovary syndrome.Gynecol Endocrinol. 2019 Mar;35(3):224-227. doi: 10.1080/09513590.2018.1519791. Epub 2018 Sep 21.
• [176] Evidence for decreased expression of APPL1 associated with reduced insulin and adiponectin receptors expression in PCOS patients.J Endocrinol Invest. 2016 Sep;39(9):1075-82. doi: 10.1007/s40618-016-0468-y. Epub 2016 Apr 13.
• [177] Coffin-Siris Syndrome with obesity, macrocephaly, hepatomegaly and hyperinsulinism caused by a mutation in the ARID1B gene.Eur J Hum Genet. 2014 Nov;22(11):1327-9. doi: 10.1038/ejhg.2014.25. Epub 2014 Feb 26.
• [178] Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis.BMC Med. 2012 Nov 30;10:153. doi: 10.1186/1741-7015-10-153.
• [179] Maternal and Paternal Infertility Disorders and Treatments and Autism Spectrum Disorder: Findings from the Study to Explore Early Development.J Autism Dev Disord. 2017 Dec;47(12):3994-4005. doi: 10.1007/s10803-017-3283-1.
• [180] CYP1A1, GSTM1 and GSTT1 genetic polymorphism is associated with susceptibility to polycystic ovaries in South Indian women.Reprod Biomed Online. 2004 Aug;9(2):194-200. doi: 10.1016/s1472-6483(10)62129-3.
• [181] Negative impact of polycystic ovary syndrome on bone health: a systematic review and meta-analysis.Hum Reprod Update. 2019 Sep 11;25(5):633-645. doi: 10.1093/humupd/dmz020.
• [182] Hyperhomocysteinemia in polycystic ovary syndrome: decreased betaine-homocysteine methyltransferase and cystathionine -synthase-mediated homocysteine metabolism.Reprod Biomed Online. 2018 Aug;37(2):234-241. doi: 10.1016/j.rbmo.2018.05.008. Epub 2018 May 22.
• [183] Lower circulating levels of CTRP12 and CTRP13 in polycystic ovarian syndrome: Irrespective of obesity.PLoS One. 2018 Dec 12;13(12):e0208059. doi: 10.1371/journal.pone.0208059. eCollection 2018.
• [184] Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome.J Clin Endocrinol Metab. 2013 Dec;98(12):E1891-900. doi: 10.1210/jc.2013-2227. Epub 2013 Oct 23.
• [185] Calpain-5 gene variants are associated with diastolic blood pressure and cholesterol levels.BMC Med Genet. 2007 Jan 16;8:1. doi: 10.1186/1471-2350-8-1.
• [186] Differential insulin and steroidogenic signaling in insulin resistant and non-insulin resistant human luteinized granulosa cells-A study in PCOS patients.J Steroid Biochem Mol Biol. 2018 Apr;178:283-292. doi: 10.1016/j.jsbmb.2018.01.008. Epub 2018 Jan 12.
• [187] Variation in stability of housekeeping genes in endometrium of healthy and polycystic ovarian syndrome women.Hum Reprod. 2012 Jan;27(1):251-6. doi: 10.1093/humrep/der363. Epub 2011 Nov 3.
• [188] Association of Luteinizing hormone and LH receptor gene polymorphism with susceptibility of Polycystic ovary syndrome.Syst Biol Reprod Med. 2019 Oct;65(5):400-408. doi: 10.1080/19396368.2019.1595217. Epub 2019 Apr 8.
• [189] Polycystic ovary syndrome is associated with genetic polymorphism in the insulin signaling gene IRS-1 but not ENPP1 in a Japanese population.Life Sci. 2007 Aug 16;81(10):850-4. doi: 10.1016/j.lfs.2007.07.023. Epub 2007 Aug 7.
• [190] RHOG-DOCK1-RAC1 Signaling Axis Is Perturbed in DHEA-Induced Polycystic Ovary in Rat Model.Reprod Sci. 2017 May;24(5):738-752. doi: 10.1177/1933719116669057. Epub 2016 Sep 22.
• [191] Different protein expression patterns associated with polycystic ovary syndrome in human follicular fluid during controlled ovarian hyperstimulation.Reprod Fertil Dev. 2012;24(7):893-904. doi: 10.1071/RD11201.
• [192] Commercial Slit Lamp Anterior Segment Photography versus Digital Compact Camera Mounted on a Standard Slit Lamp with an Adapter.Curr Eye Res. 2018 Oct;43(10):1290-1294. doi: 10.1080/02713683.2018.1490435. Epub 2018 Jul 6.
• [193] Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols.Front Pharmacol. 2017 Jun 8;8:341. doi: 10.3389/fphar.2017.00341. eCollection 2017.
• [194] Adropin in women with polycystic ovary syndrome.Endokrynol Pol. 2019;70(2):151-156. doi: 10.5603/EP.a2018.0092. Epub 2018 Nov 27.
• [195] Mechanisms in endocrinology: thyroid and polycystic ovary syndrome.Eur J Endocrinol. 2015 Jan;172(1):R9-21. doi: 10.1530/EJE-14-0295.
• [196] Polymorphisms and haplotypes of insulin-like factor 3 gene are associated with risk of polycystic ovary syndrome in Indian women.Gene. 2016 Feb 15;577(2):180-6. doi: 10.1016/j.gene.2015.11.033. Epub 2015 Nov 25.
• [197] FEM1A and FEM1B: novel candidate genes for polycystic ovary syndrome.Hum Reprod. 2008 Dec;23(12):2842-9. doi: 10.1093/humrep/den324. Epub 2008 Aug 29.
• [198] Deregulation of WNT2/FZD3/-catenin pathway compromises the estrogen synthesis in cumulus cells from patients with polycystic ovary syndrome.Biochem Biophys Res Commun. 2017 Nov 4;493(1):847-854. doi: 10.1016/j.bbrc.2017.07.057. Epub 2017 Jul 11.
• [199] Downregulation of autophagy gene expression in endometria from women with polycystic ovary syndrome.Mol Cell Endocrinol. 2017 Jan 15;440:116-124. doi: 10.1016/j.mce.2016.11.009. Epub 2016 Nov 11.
• [200] Association between copy-number variation on metabolic phenotypes and HDL-C levels in patients with polycystic ovary syndrome.Mol Biol Rep. 2017 Feb;44(1):51-61. doi: 10.1007/s11033-016-4080-1. Epub 2016 Nov 22.
• [201] Serum Concentrations of Oocyte-Secreted Factors BMP15 and GDF9 During IVF and in Women With Reproductive Pathologies.Endocrinology. 2019 Oct 1;160(10):2298-2313. doi: 10.1210/en.2019-00264.
• [202] The prevalence of Gly972Arg and C825T polymorphisms in Slovak women with polycystic ovary syndrome and their relation to the metabolic syndrome.Gynecol Endocrinol. 2010 May;26(5):356-60. doi: 10.3109/09513590903511497.
• [203] Exploring factors related to changes in body composition, insulin sensitivity and aerobic capacity in response to a 12-week exercise intervention in overweight and obese women with and without polycystic ovary syndrome.PLoS One. 2017 Aug 3;12(8):e0182412. doi: 10.1371/journal.pone.0182412. eCollection 2017.
• [204] A Low Glycemic Index Decreases Inflammation by Increasing the Concentration of Uric Acid and the Activity of Glutathione Peroxidase (GPx3) in Patients with Polycystic Ovary Syndrome (PCOS).Molecules. 2019 Apr 17;24(8):1508. doi: 10.3390/molecules24081508.
• [205] Genome-wide association study identifies GYS2 as a novel genetic factor for polycystic ovary syndrome through obesity-related condition.J Hum Genet. 2012 Oct;57(10):660-4. doi: 10.1038/jhg.2012.92. Epub 2012 Sep 6.
• [206] Metformin Regulates Key MicroRNAs to Improve Endometrial Receptivity Through Increasing Implantation Marker Gene Expression in Patients with PCOS Undergoing IVF/ICSI.Reprod Sci. 2019 Nov;26(11):1439-1448. doi: 10.1177/1933719118820466. Epub 2019 Jan 1.
• [207] Association of IRS-1 and IRS-2 genes polymorphisms with polycystic ovary syndrome: a meta-analysis.Endocr J. 2012;59(7):601-9. doi: 10.1507/endocrj.ej11-0387. Epub 2012 May 21.
• [208] High serum concentration of total inhibin in polycystic ovary syndrome.Fertil Steril. 2008 Nov;90(5):1859-63. doi: 10.1016/j.fertnstert.2007.08.082.
• [209] Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS).BMC Med Genet. 2010 Jan 21;11:12. doi: 10.1186/1471-2350-11-12.
• [210] Evaluation of the correlation between insulin like factor 3, polycystic ovary syndrome, and ovarian maldescent.Gynecol Endocrinol. 2018 Jun;34(6):481-488. doi: 10.1080/09513590.2017.1416462. Epub 2017 Dec 19.
• [211] PCOS is associated with increased CD11c expression and crown-like structures in adipose tissue and increased central abdominal fat depots independent of obesity.J Clin Endocrinol Metab. 2013 Jan;98(1):E17-24. doi: 10.1210/jc.2012-2697. Epub 2012 Nov 1.
• [212] RUNX2, GPX3 and PTX3 gene expression profiling in cumulus cells are reflective oocyte/embryo competence and potentially reliable predictors of embryo developmental competence in PCOS patients.Reprod Biol Endocrinol. 2013 Nov 26;11:109. doi: 10.1186/1477-7827-11-109.
• [213] Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose.Diabetes. 2008 Apr;57(4):801-8. doi: 10.2337/db07-0990. Epub 2008 Jan 3.
• [214] Genome-wide association study identified new susceptibility loci for polycystic ovary syndrome.Hum Reprod. 2015 Mar;30(3):723-31. doi: 10.1093/humrep/deu352. Epub 2015 Jan 8.
• [215] ERBB4 Confers Risk for Polycystic Ovary Syndrome in Han Chinese.Sci Rep. 2017 Feb 14;7:42000. doi: 10.1038/srep42000.
• [216] Association between genes encoding components of the Leutinizing hormone/Luteinizing hormone-choriogonadotrophin receptor pathway and polycystic ovary syndrome in Egyptian women.IUBMB Life. 2016 Jan;68(1):23-36. doi: 10.1002/iub.1457. Epub 2015 Dec 14.
• [217] Lipin 1 gene polymorphisms in polycystic ovary syndrome.Horm Metab Res. 2011 Jun;43(6):427-32. doi: 10.1055/s-0031-1273761. Epub 2011 Mar 29.
• [218] Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11.J Mol Med (Berl). 2019 Sep;97(9):1315-1327. doi: 10.1007/s00109-019-01809-6. Epub 2019 Jun 29.
• [219] Diagnostic Evaluation, Comorbidity Screening, and Treatment of Polycystic Ovary Syndrome in Adolescents in 3 Specialty Clinics.J Pediatr Adolesc Gynecol. 2018 Aug;31(4):367-371. doi: 10.1016/j.jpag.2018.01.007. Epub 2018 Feb 1.
• [220] Family-based association study of the MCF2L2 gene and polycystic ovary syndrome.Gynecol Obstet Invest. 2009;68(3):171-3. doi: 10.1159/000231520. Epub 2009 Jul 31.
• [221] Abnormal preantral folliculogenesis in polycystic ovaries is associated with increased granulosa cell division.J Clin Endocrinol Metab. 2007 Nov;92(11):4418-26. doi: 10.1210/jc.2007-0729. Epub 2007 Aug 14.
• [222] Association of MEP1A gene variants with insulin metabolism in central European women with polycystic ovary syndrome.Gene. 2014 Mar 10;537(2):245-52. doi: 10.1016/j.gene.2013.12.055. Epub 2014 Jan 2.
• [223] Does myo-inositol oxygenase, the only enzyme to catalyze myo-inositol in vivo, play a role in the etiology of polycystic ovarian syndrome?.Gynecol Endocrinol. 2018 May;34(5):418-421. doi: 10.1080/09513590.2017.1409710. Epub 2017 Nov 29.
• [224] Microarray evaluation of endometrial receptivity in Chinese women with polycystic ovary syndrome.Reprod Biomed Online. 2008 Sep;17(3):425-35. doi: 10.1016/s1472-6483(10)60228-3.
• [225] An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients.Reprod Biol Endocrinol. 2017 Jan 26;15(1):9. doi: 10.1186/s12958-017-0227-8.
• [226] The elusive MAESTRO gene: Its human reproductive tissue-specific expression pattern.PLoS One. 2017 Apr 13;12(4):e0174873. doi: 10.1371/journal.pone.0174873. eCollection 2017.
• [227] Mesenchymal Stem Cells Alleviate DHEA-Induced Polycystic Ovary Syndrome (PCOS) by Inhibiting Inflammation in Mice.Stem Cells Int. 2019 Sep 12;2019:9782373. doi: 10.1155/2019/9782373. eCollection 2019.
• [228] Polymorphisms of the endothelial nitric oxide synthase gene in premenopausal women with polycystic ovary syndrome.Maturitas. 2008 Nov 20;61(3):256-9. doi: 10.1016/j.maturitas.2008.08.003. Epub 2008 Sep 19.
• [229] A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells.J Mol Med (Berl). 2012 Aug;90(8):911-23. doi: 10.1007/s00109-012-0881-4. Epub 2012 Feb 21.
• [230] Increased cytochrome P450 17alpha-hydroxylase promoter function in theca cells isolated from patients with polycystic ovary syndrome involves nuclear factor-1. Mol Endocrinol. 2004 Mar;18(3):588-605.
• [231] Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study.Res Microbiol. 2019 Jan-Feb;170(1):43-52. doi: 10.1016/j.resmic.2018.09.002. Epub 2018 Oct 4.
• [232] Haptoglobin levels, but not Hp1-Hp2 polymorphism, are associated with polycystic ovary syndrome.J Assist Reprod Genet. 2017 Dec;34(12):1691-1698. doi: 10.1007/s10815-017-1030-3. Epub 2017 Sep 13.
• [233] Association study for single nucleotide polymorphisms in the CYP17A1 gene and polycystic ovary syndrome.Int J Mol Med. 2008 Aug;22(2):249-54.
• [234] Do we need readjustment of the biochemical parameters in first trimester combined aneuploidy screening test in women with polycystic ovary syndrome?.Prenat Diagn. 2014 Nov;34(11):1073-6. doi: 10.1002/pd.4430. Epub 2014 Jun 29.
• [235] PAPSS2 deficiency causes androgen excess via impaired DHEA sulfation--in vitro and in vivo studies in a family harboring two novel PAPSS2 mutations.J Clin Endocrinol Metab. 2015 Apr;100(4):E672-80. doi: 10.1210/jc.2014-3556. Epub 2015 Jan 16.
• [236] miR-155 is high-expressed in polycystic ovarian syndrome and promotes cell proliferation and migration through targeting PDCD4 in KGN cells.Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):197-205. doi: 10.1080/21691401.2019.1699826.
• [237] Phosphoprotein enriched in diabetes gene product (Ped/pea-15) is increased in omental adipose tissue of women with the polycystic ovary syndrome: ex vivo regulation of ped/pea-15 by glucose, insulin and metformin.Diabetes Obes Metab. 2011 Feb;13(2):181-4. doi: 10.1111/j.1463-1326.2010.01329.x.
• [238] Application of Spectral Domain Optical Coherence Tomography to Objectively Evaluate Posterior Capsular Opacity In Vivo.J Ophthalmol. 2018 Dec 23;2018:5461784. doi: 10.1155/2018/5461784. eCollection 2018.
• [239] Circulating levels and subcutaneous adipose tissue gene expression of pigment epithelium-derived factor in polycystic ovary syndrome and normal women: a case control study.Reprod Biol Endocrinol. 2013 Aug 14;11:77. doi: 10.1186/1477-7827-11-77.
• [240] PGC-1 protects against oxidized low-density lipoprotein and luteinizing hormone-induced granulosa cells injury through ROS-p38 pathway.Hum Cell. 2019 Jul;32(3):285-296. doi: 10.1007/s13577-019-00252-6. Epub 2019 Apr 16.
• [241] Association of the (AU)AT-rich element polymorphism in PPP1R3 with hormonal and metabolic features of polycystic ovary syndrome.J Clin Endocrinol Metab. 2004 Jun;89(6):2973-6. doi: 10.1210/jc.2003-031189.
• [242] Association study of AMP-activated protein kinase subunit genes in polycystic ovary syndrome.Eur J Endocrinol. 2009 Sep;161(3):405-9. doi: 10.1530/EJE-09-0245. Epub 2009 Jul 2.
• [243] miR?8?p suppresses cell proliferation and weakens the progression of polycystic ovary syndrome by targeting prokineticin?.Mol Med Rep. 2019 Sep;20(3):2468-2475. doi: 10.3892/mmr.2019.10446. Epub 2019 Jul 1.
• [244] Bit1-a potential positive regulator of epithelial-mesenchymal transition in lens epithelial cells.Graefes Arch Clin Exp Ophthalmol. 2016 Jul;254(7):1311-8. doi: 10.1007/s00417-016-3357-3. Epub 2016 Apr 28.
• [245] Association between Common Genetic Variants and Polycystic Ovary Syndrome Risk in a Chinese Han Population.J Clin Res Pediatr Endocrinol. 2016 Dec 1;8(4):405-410. doi: 10.4274/jcrpe.2784. Epub 2016 May 23.
• [246] Replication study of RAD54B and GREB1 polymorphisms and risk of PCOS in Han Chinese.Reprod Biomed Online. 2013 Sep;27(3):316-21. doi: 10.1016/j.rbmo.2013.05.007. Epub 2013 May 22.
• [247] Correlation between thrombophilia and recurrent pregnancy loss in patients with polycystic ovary syndrome: a comparative study.J Chin Med Assoc. 2013 May;76(5):282-8. doi: 10.1016/j.jcma.2013.01.009. Epub 2013 Mar 20.
• [248] Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.Diabetes. 2008 Jun;57(6):1501-7. doi: 10.2337/db08-0127. Epub 2008 Mar 28.
• [249] Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases.Int J Mol Sci. 2017 Jul 29;18(8):1651. doi: 10.3390/ijms18081651.
• [250] Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS).Clin Chim Acta. 2017 Jan;464:155-159. doi: 10.1016/j.cca.2016.11.010. Epub 2016 Nov 9.
• [251] The effect of serum and follicular fluid secreted frizzle-related protein-5 on in vitro fertilization outcomes in patients with polycystic ovary syndrome.Mol Biol Rep. 2018 Dec;45(6):2037-2044. doi: 10.1007/s11033-018-4360-z. Epub 2018 Sep 7.
• [252] Effect of GnRHR polymorphisms on in vitro fertilization and embryo transfer in patients with polycystic ovary syndrome.J Hum Genet. 2017 Dec;62(12):1065-1071. doi: 10.1038/jhg.2017.85. Epub 2017 Sep 7.
• [253] MiRNA-335-5p negatively regulates granulosa cell proliferation via SGK3 in PCOS.Reproduction. 2018 Nov;156(5):439-449. doi: 10.1530/REP-18-0229.
• [254] Polymorphism in postinsulin receptor signaling pathway is not associated with polycystic ovary syndrome.Fertil Steril. 2008 Dec;90(6):2298-303. doi: 10.1016/j.fertnstert.2007.10.079. Epub 2008 Feb 4.
• [255] SORCS1 polymorphism and insulin secretion in obese women with polycystic ovary syndrome.Gynecol Endocrinol. 2016;32(5):395-8. doi: 10.3109/09513590.2015.1126818. Epub 2016 Jan 6.
• [256] Association study of androgen signaling pathway genes in polycystic ovary syndrome.Fertil Steril. 2016 Feb;105(2):467-73.e4. doi: 10.1016/j.fertnstert.2015.09.043. Epub 2015 Oct 20.
• [257] Association of TRB3 Q84R polymorphism with polycystic ovary syndrome in Chinese women.Reprod Biol Endocrinol. 2011 Apr 14;9:46. doi: 10.1186/1477-7827-9-46.
• [258] Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.Dan Med J. 2014 Jul;61(7):B4890.
• [259] Genetic variations of follicle stimulating hormone receptor are associated with polycystic ovary syndrome.Int J Mol Med. 2010 Jul;26(1):107-12. doi: 10.3892/ijmm_00000441.
• [260] Differences in connective tissue gene expression between normally functioning, polycystic and post-menopausal ovaries.Mol Hum Reprod. 2004 Jan;10(1):7-14. doi: 10.1093/molehr/gah003.
• [261] The risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis.Clin Endocrinol (Oxf). 2018 Feb;88(2):169-184. doi: 10.1111/cen.13477. Epub 2017 Oct 16.
• [262] Construction and analysis of a lncRNA (PWRN2)-mediated ceRNA network reveal its potential roles in oocyte nuclear maturation of patients with PCOS.Reprod Biol Endocrinol. 2018 Aug 3;16(1):73. doi: 10.1186/s12958-018-0392-4.
• [263] BMI-associated alleles do not constitute risk alleles for polycystic ovary syndrome independently of BMI: a case-control study.PLoS One. 2014 Jan 31;9(1):e87335. doi: 10.1371/journal.pone.0087335. eCollection 2014.
• [264] Overexpression of salusin- is associated with poor prognosis in ovarian cancer.Oncol Rep. 2017 Mar;37(3):1826-1832. doi: 10.3892/or.2017.5429. Epub 2017 Feb 7.
• [265] Relationship between abnormal TOX3 gene methylation and polycystic ovarian syndrome.Eur Rev Med Pharmacol Sci. 2017 May;21(9):2034-2038.
• [266] FGF2 antagonizes aberrant TGF regulation of tropomyosin: role for posterior capsule opacity.J Cell Mol Med. 2017 May;21(5):916-928. doi: 10.1111/jcmm.13030. Epub 2016 Dec 15.
• [267] Tropomyosin 2 heterozygous knockout in mice using CRISPR-Cas9 system displays the inhibition of injury-induced epithelial-mesenchymal transition, and lens opacity.Mech Ageing Dev. 2018 Apr;171:24-30. doi: 10.1016/j.mad.2018.03.001. Epub 2018 Mar 3.